{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:14:57Z","timestamp":1762074897729,"version":"build-2065373602"},"reference-count":73,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2023,2,23]]},"DOI":"10.1080\/10428194.2022.2136969","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T23:37:59Z","timestamp":1667432279000},"page":"540-550","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["<i>TP53<\/i>\n            -altered higher-risk myelodysplastic syndromes\/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs"],"prefix":"10.1080","volume":"64","author":[{"given":"Somedeb","family":"Ball","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, University of South Florida\/H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Hematology, Yale Cancer Center, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013343"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014472"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.143"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003508"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30203"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003159"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003988"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02341"},{"key":"e_1_3_2_14_1","volume-title":"The first-in-class anti-cd47 antibody magrolimab combined with azacitidine is well-tolerated and effective in MDS patients: phase 1B results","author":"Sallman D","year":"2020","unstructured":"Sallman D, Malki MA, Asch A, et\u00a0al. The first-in-class anti-cd47 antibody magrolimab combined with azacitidine is well-tolerated and effective in MDS patients: phase 1B results. Hague, Netherlands: European Hematology Association; 2020."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.180"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-356014"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0377-0"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-763086"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13968"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207396"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1559"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.3.988-1002.2005"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1002242"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17157"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006158"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0351-2"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375758"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1008-z"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12203"},{"key":"e_1_3_2_30_1","unstructured":"Bernard E Tuechler H Greenberg PL et\u00a0al. Molecular international prognosis scoring system for myelodysplastic syndromes. American Society of Hematology Annual Meeting; December 2021 Atlanta GA USA."},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003120"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.304"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605949"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124500"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3616"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611604"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-754796"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002727"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147639"},{"key":"e_1_3_2_43_1","unstructured":"US Food and Drug Administration. 2020 FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. Silver Spring\u00a0(MD): US Food and Drug Administration; 2020."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145646"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145639"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0125"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30210-6"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33689"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.03.003"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00021"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.218453"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153286"},{"key":"e_1_3_2_54_1","unstructured":"Aprea Therapeutics. Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS). 2020."},{"key":"e_1_3_2_55_1","doi-asserted-by":"crossref","unstructured":"Garcia-Manero G Goldberg AD Winer ES et\u00a0al. Phase I and expansion study of eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-mutant Acute Myeloid Leukemia (AML). American Society of Hematology Annual Meeting; December 2021 Atlanta GA USA.","DOI":"10.1182\/blood-2021-148940"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00181"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103164"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.046"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137345"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-120170"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7017"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7020"},{"key":"e_1_3_2_63_1","volume-title":"Combined blockade of CD47-Sirpa interaction By 5F9 (Magrolimab) and azacitidine\/venetoclax therapy facilitates macrophage-mediated anti-leukemia efficacy in AML pre-clinical models. American Society of Hematology Annual Meeting","author":"Jia Y","year":"2021","unstructured":"Jia Y, Zhang Q, Weng C, et\u00a0al. Combined blockade of CD47-Sirpa interaction By 5F9 (Magrolimab) and azacitidine\/venetoclax therapy facilitates macrophage-mediated anti-leukemia efficacy in AML pre-clinical models. American Society of Hematology Annual Meeting; December 2021, Atlanta, GA, USA."},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-153638"},{"key":"e_1_3_2_65_1","volume-title":"Sabatolimab plus hypomethylating agents (hmas) in patients (pts) with high-\/very high-risk myelodysplastic syndrome (HR\/VHR-MDS) and acute myeloid leukemia (AML): subgroup analysis of a phase 1 study","author":"Wei A","year":"2021","unstructured":"Wei A, Esteve J, Porkka K, et\u00a0al. Sabatolimab plus hypomethylating agents (hmas) in patients (pts) with high-\/very high-risk myelodysplastic syndrome (HR\/VHR-MDS) and acute myeloid leukemia (AML): subgroup analysis of a phase 1 study. Hague, Netherlands: European Hematology Association; 2021."},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.023"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002512"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463"},{"key":"e_1_3_2_69_1","doi-asserted-by":"crossref","unstructured":"Zeidan A Boss I Beach CL et\u00a0al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Adv. 2022;6(7):2207\u20132218.","DOI":"10.1182\/bloodadvances.2021005487"},{"key":"e_1_3_2_70_1","doi-asserted-by":"crossref","unstructured":"Zeidan A Boss I Beach CL et\u00a0al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 2022;6(7):2219\u20132229.","DOI":"10.1182\/bloodadvances.2021006138"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa5693"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153514"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2022.2136969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T13:46:26Z","timestamp":1708436786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2022.2136969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2,23]]}},"alternative-id":["10.1080\/10428194.2022.2136969"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2022.2136969","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"type":"print","value":"1042-8194"},{"type":"electronic","value":"1029-2403"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}